Keyphrases
Insulin Sensitivity
100%
Metabolic Effects
100%
Adiposity
100%
Randomized Clinical Trial
100%
Olanzapine
100%
Antipsychotics
100%
Aripiprazole
83%
Risperidone
66%
Magnetic Resonance Imaging
33%
Total Body Fat
33%
Dual-energy X-ray Absorptiometry
33%
Treatment Interaction
33%
Disruptive Behavioral Disorders
33%
Clinically Significant
16%
No Significant Difference
16%
Body Composition
16%
Aggression
16%
Psychiatric Disorders
16%
African American
16%
Disappearance Rate
16%
Insulin
16%
Adipose Tissue
16%
Cardiometabolic Disease
16%
Missouri
16%
St. Louis
16%
Overweight or Obesity
16%
Isotopically Labeled
16%
Criterion Standards
16%
Behavioral Improvement
16%
Risk-benefit
16%
Subcutaneous Fat
16%
Intention-to-treat
16%
Abdominal Fat
16%
Sampling Effect
16%
Hyperinsulinemic-euglycemic Clamp
16%
Metropolitan Areas
16%
Hepatic Tissue
16%
Non-psychotic Disorders
16%
Abdominal Adiposity
16%
1-to-1
16%
Time Effect
16%
Pooled Study
16%
Antipsychotic Use
16%
First Exposure
16%
Antipsychotic-naïve
16%
Risperdone
16%
Medicine and Dentistry
Insulin Sensitivity
100%
Obesity
100%
Randomized Clinical Trial
100%
Typical Antipsychotic
100%
Olanzapine
100%
Aripiprazole
83%
Risperidone
66%
Drug Therapy
33%
Magnetic Resonance Imaging
33%
Body Fat
33%
Radioactive Tracer
33%
Cognition
33%
Absorptiometry
33%
Adipose Tissue
16%
Intention-to-Treat Analysis
16%
Prematurity
16%
Subcutaneous Fat
16%
Abdominal Obesity
16%
Abdominal Fat
16%
Body Composition Assessment
16%
Pharmacology, Toxicology and Pharmaceutical Science
Obesity
100%
Randomized Clinical Trial
100%
Typical Antipsychotic
100%
Olanzapine
100%
Antipsychotic
83%
Aripiprazole
83%
Risperidone
66%
Tracer
33%
Behavior Disorder
33%
Prematurity
16%
Abdominal Obesity
16%
Neuroscience
Typical Antipsychotic
100%
Olanzapine
100%
Aripiprazole
83%
Antipsychotic
83%
Risperidone
66%
Behavior Disorder
33%
Magnetic Resonance Imaging
33%
Adipose Tissue
16%